PT  - JOURNAL ARTICLE
AU  - Hannes Treiber
AU  - Alexander König
AU  - Albrecht Neesse
AU  - Annika Richter
AU  - Carsten Oliver Sahlmann
AU  - Arne Strauss
TI  - Liver Enzyme Elevation After <sup>177</sup>Lu-PSMA Radioligand Therapy for Metastasized Castration-Resistant Prostate Cancer
AID  - 10.2967/jnumed.120.258533
DP  - 2021 Jul 01
TA  - Journal of Nuclear Medicine
PG  - 1016--1019
VI  - 62
IP  - 7
4099  - http://jnm.snmjournals.org/content/62/7/1016.short
4100  - http://jnm.snmjournals.org/content/62/7/1016.full
SO  - J Nucl Med2021 Jul 01; 62
AB  - 177Lu-PSMA radioligand therapy is a promising new option for patients with metastasized castration-resistant prostate cancer, and the spectrum of adverse events with this treatment has to be evaluated. Here, we describe the case of a patient with M1c disease (metastasis to the mediastinum, lungs, bones, and liver) who presented with elevated liver enzyme levels after receiving 177Lu-PSMA radioligand therapy for castration-resistant prostate cancer. Pretreatment 68Ga-PSMA PET/CT showed at least 4 liver lesions with low uptake. Overall, the liver uptake was inhomogeneous. Liver biopsy was performed subsequently.